Zyada Manal M, Grawish Mohammed E, Elsabaa Heba M
Oral Pathology Department, Faculty of Dentistry, Mansoura University, 35516 Egypt.
Ann Diagn Pathol. 2009 Oct;13(5):313-21. doi: 10.1016/j.anndiagpath.2009.06.003. Epub 2009 Aug 14.
The expression of cyclooxygenase 2 (COX-2) is induced by growth factors, tumor promoters, and cytokines. It is correlated with carcinogenesis and apoptosis inhibition. This study was designed to investigate the expression of COX-2 and BCl-2 and to correlate their expressions with the clinicopathologic features in the mucoepidermoid carcinoma (MEC). The expression of COX-2 and BCl-2 proteins was investigated in 16 archival tumor tissues of MEC using the streptavidin-biotin complex technique. Clinical information was obtained through the computerized retrospective database from the tumor registry between 2001 and 2007. It revealed that grading system of MEC did not correlate with the presence or absence of node metastasis. The expression of COX-2 and BCl-2 was variably expressed in all the examined specimens. COX-2 and BCl-2 immunoreactivity was observed mainly in the cytoplasm of neoplastic cells. As regard the clinicopathologic parameters, there was no significant difference in expression rates of COX-2 in patients among age, sex, and MEC grades (P > .05). However, the expression of COX-2 in node-positive tumors was significantly higher than that of node-negative tumors (P = .001). For BCL-2 expression, there was no significant difference in expression rates of BCl-2 in patients among age, sex, site, clinical stage, and lymph node metastasis (P > .05), whereas a high significant difference was observed between BCl-2 staining index and MEC grades (P = .027). Moreover, there is a positive correlation between COX-2 expression and BCL-2 staining index (P = .000). COX-2 is a good predictor for lymph node metastasis as well as ideal therapeutic target for the prevention or treatment of MEC. BCl-2 and COX-2 are potentially useful prognostic markers for MEC.
环氧化酶2（COX-2）的表达可由生长因子、肿瘤启动子和细胞因子诱导。它与肿瘤发生及细胞凋亡抑制相关。本研究旨在探讨COX-2和Bcl-2的表达，并将它们的表达与黏液表皮样癌（MEC）的临床病理特征相关联。采用链霉亲和素-生物素复合物技术，对16例MEC存档肿瘤组织中COX-2和Bcl-2蛋白的表达进行了研究。通过计算机化回顾性数据库，获取了2001年至2007年间肿瘤登记处的临床信息。结果显示，MEC的分级系统与有无淋巴结转移无关。在所有检测标本中，COX-2和Bcl-2的表达各不相同。COX-2和Bcl-2免疫反应主要见于肿瘤细胞的细胞质。就临床病理参数而言，COX-2在不同年龄、性别和MEC分级患者中的表达率无显著差异（P＞0.05）。然而，有淋巴结转移肿瘤中COX-2的表达显著高于无淋巴结转移肿瘤（P = 0.001）。对于Bcl-2表达，在不同年龄、性别、部位、临床分期和淋巴结转移的患者中，Bcl-2的表达率无显著差异（P＞0.05），而Bcl-2染色指数与MEC分级之间存在高度显著差异（P = 0.027）。此外，COX-2表达与Bcl-2染色指数之间存在正相关（P = 0.000）。COX-2是淋巴结转移的良好预测指标，也是预防或治疗MEC的理想治疗靶点。Bcl-2和COX-2是MEC潜在有用的预后标志物。
